Clinical Trial Update: Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes an investigational RPGR gene therapy for X-linked retinitis pigmentosa, currently in Phase 1/2 and recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Retinitis Pigmentosa

Drugs mentioned

• RPGR gene therapy

Snippet

Sponsor: Frontera Therapeutics | Conditions: X-Linked Retinitis Pigmentosa (XLRP) | Phase 1, Phase 2 | Status: RECRUITING